DK1572246T3 - Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater - Google Patents

Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater

Info

Publication number
DK1572246T3
DK1572246T3 DK03799680T DK03799680T DK1572246T3 DK 1572246 T3 DK1572246 T3 DK 1572246T3 DK 03799680 T DK03799680 T DK 03799680T DK 03799680 T DK03799680 T DK 03799680T DK 1572246 T3 DK1572246 T3 DK 1572246T3
Authority
DK
Denmark
Prior art keywords
magnetic particles
gembis
particles coated
novel compositions
phosphonate derivatives
Prior art date
Application number
DK03799680T
Other languages
Danish (da)
English (en)
Inventor
Marc Port
Claire Corot
Isabelle Raynal
Olivier Rousseaux
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of DK1572246T3 publication Critical patent/DK1572246T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03799680T 2002-12-20 2003-12-19 Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater DK1572246T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216410A FR2848850B1 (fr) 2002-12-20 2002-12-20 Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
PCT/FR2003/003855 WO2004058275A2 (fr) 2002-12-20 2003-12-19 Compositions de particules magnetiques recouvertes de derives gem-bisphosphonates

Publications (1)

Publication Number Publication Date
DK1572246T3 true DK1572246T3 (da) 2009-06-08

Family

ID=32406319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03799680T DK1572246T3 (da) 2002-12-20 2003-12-19 Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater

Country Status (14)

Country Link
US (2) US7780953B2 (ja)
EP (1) EP1572246B1 (ja)
JP (1) JP4638738B2 (ja)
CN (1) CN100358584C (ja)
AT (1) ATE423575T1 (ja)
AU (1) AU2003299388A1 (ja)
BR (1) BR0316886A (ja)
CA (1) CA2510531C (ja)
DE (1) DE60326383D1 (ja)
DK (1) DK1572246T3 (ja)
ES (1) ES2321709T3 (ja)
FR (1) FR2848850B1 (ja)
PT (1) PT1572246E (ja)
WO (1) WO2004058275A2 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20050114109A1 (en) * 2002-02-07 2005-05-26 Arnaout M. A. STRUCTURE OF INTEGRIN ALPHA V-beta 3 EXTRACELLULAR DOMAIN COMPLEXED WITH LIGAND
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
US8118754B1 (en) 2007-11-15 2012-02-21 Flynn Edward R Magnetic needle biopsy
US20070250139A1 (en) * 2004-05-07 2007-10-25 John Kanzius Enhanced systems and methods for RF-induced hyperthermia II
US7510555B2 (en) * 2004-05-07 2009-03-31 Therm Med, Llc Enhanced systems and methods for RF-induced hyperthermia
US20050251234A1 (en) * 2004-05-07 2005-11-10 John Kanzius Systems and methods for RF-induced hyperthermia using biological cells and nanoparticles as RF enhancer carriers
US20050251233A1 (en) * 2004-05-07 2005-11-10 John Kanzius System and method for RF-induced hyperthermia
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US9964469B2 (en) 2005-02-28 2018-05-08 Imagion Biosystems, Inc. Magnetic needle separation and optical monitoring
US7598199B2 (en) * 2005-05-10 2009-10-06 Massachusetts Institute Of Technology Catalytic nanoparticles for nerve-agent destruction
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
WO2011057146A1 (en) 2009-11-06 2011-05-12 Scientific Nanomedicine, Inc. Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
US8447379B2 (en) 2006-11-16 2013-05-21 Senior Scientific, LLC Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
FR2921837B1 (fr) * 2007-10-05 2015-07-31 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice organique couplee a des ligands de ciblage
WO2009117071A1 (en) * 2008-03-17 2009-09-24 Cabot Corporation Modified pigments having reduced phosphate release, and dispersions and inkjet ink compositions therefrom
US8057976B2 (en) * 2008-08-21 2011-11-15 Empire Technology Development Llc Method for producing toner
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
US10194825B2 (en) 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
JP5778769B2 (ja) * 2010-07-21 2015-09-16 ソルベイ チャイナ カンパニー、リミテッドＳｏｌｖａｙ （Ｃｈｉｎａ） Ｃｏ．，Ｌｔｄ． 無機基材を安定な重合層で被覆する方法
KR101805873B1 (ko) 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
IT1401882B1 (it) * 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
EP2651456A1 (en) * 2010-12-15 2013-10-23 General Electric Company Nanoparticle composition and associated methods thereof
EP2572736A1 (en) * 2011-09-23 2013-03-27 Spago Imaging AB Nanostructures comprising manganese
FR2990433A1 (fr) * 2012-05-10 2013-11-15 Surfactis Technologies Compositions catanioniques de recouvrement de surface par des molecules phosphoniques et amines
CN105524492A (zh) * 2016-01-12 2016-04-27 四川大学 一种简易低成本的磁性微粒表面活性基团引入方法
CN108203448B (zh) * 2016-12-19 2020-12-15 香港中文大学 促进矿化并提供生物活性离子的持续释放的可注射水凝胶
CN111840547B (zh) * 2020-06-15 2023-04-28 山西振东泰盛制药有限公司 注射用培美曲塞磁性自组装纳米复合颗粒制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440646A (en) * 1965-08-24 1984-04-03 Plains Chemical Development Co. Chelation
GB1435295A (en) * 1973-11-19 1976-05-12 Research Corp Bone seeking technetium-99m complex
US4120890A (en) * 1976-01-21 1978-10-17 Henkel Kommanditgesellschaft Auf Aktien Diphosphonoalkane carboxylic acids, process of preparation and methods of use
FR2461521A1 (fr) * 1979-07-20 1981-02-06 Anvar Fluides magnetiques, notamment ferrofluides, et procede pour leur obtention
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE191086T1 (de) * 1994-07-27 2000-04-15 Pilgrimm Herbert Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung
JPH08268987A (ja) * 1995-02-24 1996-10-15 Bristol Myers Squibb Co テトラリニル−，及びインダニル−エチルアミド誘導体
FR2736197B1 (fr) * 1995-06-29 1997-09-12 Univ Paris Curie Nanoparticules magnetiques couplees a de l'annexine et leur utilisation
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
WO2001037721A2 (en) * 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues

Also Published As

Publication number Publication date
CA2510531A1 (fr) 2004-07-15
EP1572246A2 (fr) 2005-09-14
WO2004058275A2 (fr) 2004-07-15
BR0316886A (pt) 2005-10-25
FR2848850A1 (fr) 2004-06-25
JP2006513198A (ja) 2006-04-20
CN100358584C (zh) 2008-01-02
FR2848850B1 (fr) 2005-06-24
CA2510531C (fr) 2012-09-04
US20100297025A1 (en) 2010-11-25
PT1572246E (pt) 2009-05-22
EP1572246B1 (fr) 2009-02-25
WO2004058275A3 (fr) 2004-12-09
AU2003299388A1 (en) 2004-07-22
CN1744920A (zh) 2006-03-08
AU2003299388A8 (en) 2004-07-22
ES2321709T3 (es) 2009-06-10
ATE423575T1 (de) 2009-03-15
JP4638738B2 (ja) 2011-02-23
DE60326383D1 (de) 2009-04-09
US7780953B2 (en) 2010-08-24
US20040253181A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DK1572246T3 (da) Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater
AU3599801A (en) Reagents for the quantitation of active oxygen
MXPA04006581A (es) Derivados de sulfonato y su empleo como acidos latentes.
DE60032780D1 (de) Tetrahydroquinolin-derivate
AR057914A1 (es) Compuestos organicos de azufre y su uso
DE60123933D1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
ATE294840T1 (de) Bis-silane enthaltende sperrschichten
MXPA04004347A (es) Nuevos fotoindicadores difuncionales.
DE60217867D1 (de) Neue picolinaminderivate und deren verwendung als fungizide
MXPA05011847A (es) Revestimientos fotocurados y estabilizados.
AU7824900A (en) Compounds and methods for inhibiting mrp1
ATE497948T1 (de) Bicyclische verbindungen
BRPI0601766A (pt) composições contendo aminas e seu uso
TW427979B (en) A condensed piperidine compound
EP1398306A3 (en) A (1'R, 2'S, 5'R)-3-l-Menthoxyalkan-1-ol cooling sensate
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
BRPI0206922B8 (pt) composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância
DE50203353D1 (de) 1,3-dihydroxybenzol-derivate und diese verbindungen enthaltende färbemittel
RS51147B (sr) Poboljšani postupak za prečišćavanje perindoprila
ATE254099T1 (de) Trimethyldecen-verbindungen
ATE377630T1 (de) Siliciumhaltige verbindung, zusammensetzung und isolierfilm
BR9902096A (pt) Pitazóis.
DK1592303T3 (da) Behandling af slam eller opslæmninger
WO2003043973A3 (en) Amine phenolic compounds and their use as hardeners and/or accelerators in epoxy coatings